KMP and senior management transferred to buyer post slump sale

Ceo ResignedKmp ResignedManagement Changes View source PDF Explain this filing

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.5%Reaction day

₹14.72

prior close

₹14.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-4.5% vs market

On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+1.5

15m

+1.5

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-3.5+0.9-4.5

Next day

+8.0+0.8+7.2

+1.5+0.7+0.7

-0.5+1.3-1.8

-6.4+0.5-6.9

-4.9+0.4-5.2

+1.8-1.5+3.3

15d

+22.3-2.4+24.7

+43.1-4.4+47.5

+17.2-7.2+24.4

-8.4-5.0-3.4

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Following completion of the business transfer agreement with Ceph Lifesciences Private Limited dated July 7, 2025, four key managerial and senior personnel have been transferred to the purchaser effective November 10, 2025. These include CEO Amit Chadah, President Harparkash Singh Gill, VP Technical Parveen Kumar Sareen, and Wholetime Director R&D Dr. Surulichamy Senthilkumar. Dr. Senthilkumar will continue as Non-Executive Director without remuneration or sitting fee.

Likely market impact

Major leadership transition tied to business divestiture; shareholders should watch for succession plans and impact on remaining operations.